Syndax

CompanyUnited States

Syndax develops one asset. Mostly antibody acting on inflammation and CSF1R; based in the United States.

1
Asset
Furthest stage
Not known
0
Trials
1
Signal

Pipeline

1
  • Niktimvo

    Blocks CSF1R signaling to reduce macrophage-mediated inflammation and fibrosis.

    Discontinued, Antibody, Inflammation, CSF1R

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Signals1
  • Similar companies6

Intelligence